中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
LYECs: lysosome-enhancing compounds as potential therapeutic approaches for Alzheimer disease

文献类型：期刊论文

作者Yin, Limin3,4; Zhou, Yu1,2; Liu, Hong1,2; Li, Yang3,4
刊名AUTOPHAGY
出版日期2022-10-09
页码2
关键词Alzheimer's disease lysosome biogenesis lysosome-enhancing compounds TFEB
ISSN号1554-8627
DOI10.1080/15548627.2022.2131247
通讯作者Zhou, Yu(zhouyu@simm.ac.cn) ; Liu, Hong(hliu@simm.ac.cn) ; Li, Yang(oceanyangli@fudan.edu.cn)
英文摘要More than 55 million people are suffering from Alzheimer's disease (AD), but there is still no effective treatment for it. Therefore, novel therapeutic approaches and regulatory mechanisms of protein quality control need to be further evaluated and dissected. The lysosome is one of the major degradative organelles that maintain cellular homeostasis and protein quality control. In our recent study, we have identified a group of LYsosome-Enhancing Compounds (LYECs), which significantly promote the activation of TFEB (transcription factor EB) and lysosome biogenesis via inhibiting dopamine transporters (DAT). Injection of LH2-051, a member of the LYECs identified in this study, significantly improves learning, memory, and cognitive function of APP-PSEN1 mice, in which the enhanced capability of lysosomal degradation promotes the clearance of amyloid protein aggregates. In summary, this study reports novel mechanisms of neurotransporter-mediated lysosome biogenesis and shows that DAT inhibition can alleviate the pathogenesis of Alzheimer's disease.
资助项目Ministry of Science and Technology of the People's Republic of China[2022ZD0213000] ; National Natural Science Foundation of China[92057103] ; National Natural Science Foundation of China[31872820] ; National Natural Science Foundation of China[91953108] ; National Natural Science Foundation of China[82130105] ; National Natural Science Foundation of China[82121005] ; National Natural Science Foundation of China[82173656] ; Shanghai Basic Research Program[18ZR1404000] ; State Key Laboratory of Drug Research[SIMM2004KF-09]
WOS研究方向Cell Biology
语种英语
WOS记录号WOS:000865642100001
出版者TAYLOR & FRANCIS INC
源URL[http://119.78.100.183/handle/2S10ELR8/302757]  
专题新药研究国家重点实验室
通讯作者Zhou, Yu; Liu, Hong; Li, Yang
作者单位1.Univ Chinese Acad Sci, Sch Pharm, Beijing, Peoples R China
2.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai, Peoples R China
3.Fudan Univ, MOE Frontiers Ctr Brain Sci, Sch Basic Med Sci, Key Lab Metab & Mol Med,Minist Educ, Shanghai, Peoples R China
4.Fudan Univ, State Key Lab Med Neurobiol, Sch Basic Med Sci, Dept Pharmacol, Shanghai, Peoples R China
推荐引用方式
GB/T 7714		 Yin, Limin,Zhou, Yu,Liu, Hong,et al. LYECs: lysosome-enhancing compounds as potential therapeutic approaches for Alzheimer disease[J]. AUTOPHAGY,2022:2.
APA Yin, Limin,Zhou, Yu,Liu, Hong,&Li, Yang.(2022).LYECs: lysosome-enhancing compounds as potential therapeutic approaches for Alzheimer disease.AUTOPHAGY,2.
MLA Yin, Limin,et al."LYECs: lysosome-enhancing compounds as potential therapeutic approaches for Alzheimer disease".AUTOPHAGY (2022):2.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。